
|Videos|January 8, 2019
Expert Addresses Major Challenge in Treatment of Myeloma
Author(s)David M. Siegel, MD, PhD
David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Advertisement
David S. Siegel, MD, PhD, chief of the division of multiple myeloma at John Theurer Cancer Center, Hackensack Meridian Health, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
According to Siegel, there is a notion that it is imperative to change classes of drugs when there is progression of disease. This is believed by both community oncologists and myeloma experts alike.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5



































